Table 2 CD200 expression is strongly associated with core-binding factor AML, CEBPA and RUNX1 mutations
From: CD200 in acute myeloid leukemia: marked upregulation in CEBPA biallelic mutated cases
N = 431 | CD200 expression | %Positive cases | p-value | ||
|---|---|---|---|---|---|
P0 | P1 | P2 | |||
N | N | N | |||
FLT3 | 86 | 35 | 17 | 37.6% | ns |
NPM1 | 118 | 21 | 7 | 19.1% | < 0.001 |
RUNX1 | 21 | 15 | 10 | 54.3% | < 0.05 |
RUNX1/RUNX1T1 | 3 | 11 | 2 | 81.3% | < 0.001 |
CBFB-MYH11 | 7 | 12 | 0 | 63.2% | < 0.001 |
IDH1/2 | 58 | 18 | 6 | 29.3% | ns |
Biallelic CEBPA | 0 | 4 | 4 | 100% | < 0.001 |
KMT2A | 15 | 7 | 2 | 37.5% | ns |
TP53 | 22 | 6 | 1 | 24.1% | ns |
DAT | |||||
DNMT3A TET2 ASXL1/2 | 82 33 41 | 20 11 17 | 7 9 7 | 24.8% 37.8% 36.9% | ns ns ns |
Spliceosome | |||||
SF3B1 SRSF2 U2AF1 ZRSR2 | 5 20 10 4 | 3 6 0 3 | 2 2 2 0 | 50.0% 28.6% 16.7% 42.9% | ns ns ns ns |
WT1 | 15 | 9 | 4 | 46.4% | ns |
GATA2 | 5 | 5 | 4 | 64.2% | < 0.05 |
ETV6 | 1 | 3 | 2 | 83.3% | < 0.05 |
PHF6 | 3 | 1 | 3 | 57.1% | < 0.05 |
ZBTZ7A | 3 | 6 | 1 | 70.0% | < 0.05 |
Other alterations | 219 | 73 | 26 | 31.1% | ns |
No mutations | 20 | 5 | 0 | 20.0% | ns |